UBX UNITY Biotechnology Inc

As filed with the Securities and Exchange Commission on March 7, 2025

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Unity Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)			26-4726035 (I.R.S. Employer Identification No.)
285 East grand Avenue South San Francisco, CA (Address of Principal Executive Officer)			94080 (Zip Code)

 

2018 Incentive Award Plan

2018 Employee Stock Purchase Plan

(Full title of the plan)

Anirvan Ghosh, Ph.D. Chief Executive Officer

Unity Biotechnology, Inc.

285 East Grand Avenue
South San Francisco, CA 94080

(Name and address of agent for service)

 

(650) 416-1192

(Telephone number, including area code, of agent for service)

 

Copy to:
Alexander Nguyen, Esq. Chief Legal Officer and Corporate Secretary Unity Biotechnology, Inc. 285 East Grand Avenue South San Francisco, CA 94080 Telephone: (650) 416-1192 Facsimile: (415) 656-4371			Joshua M. Dubofsky, Esq. Erica Kassman, Esq. Latham & Watkins LLP 140 Scott Drive Menlo Park, CA 94025 Telephone: (650) 463-2631 Facsimile: (714) 755-8290

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☒		Smaller reporting company	☒
			Emerging growth company	☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

---

Proposed sale to take place as soon after the effective date of the

registration statement as awards under the plans are exercised and/or vest.

 

---

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 1,011,912 shares of the Registrant’s common stock, par value $0.0001 per share, issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-278679, 333-270567, 333-263576, 333-254619, 333-237088, 333-230086, and 333-224726) are effective: (i) the 2018 Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 843,260 shares of common stock and (ii) the 2018 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 168,652 shares of common stock.

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON

FORM S-8

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on May 7, 2018 (File No. 333-224726), March 6, 2019 (File No. 333-230086), March 11, 2020 (File No. 333-237088) and March 23, 2021 (File No. 333-254619), March 15, 2022 (File No. 333-263576), March 15, 2023 (File No. 333-270567), and April 15, 2024 (File No. 333-278679) are incorporated by reference herein to the extent not modified or superseded hereby or by any subsequently filed document, except for Item 8, which is being updated by this Registration Statement on Form S-8.

 

---

Item 8. Exhibits.

Incorporated by Reference

Filed Herewith

Exhibit Number

Exhibit Description

Form

Date

Number

4.1

Amended and Restated Certificate of Incorporation of Unity Biotechnology, Inc.

8-K

5-7-18

3.1

4.2

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Unity Biotechnology, Inc.

8-K

10-19-22

3.1

4.3

Amended and Restated Bylaws of Unity Biotechnology, Inc.

10-K

4-15-24

3.3

4.4

Form of Common Stock Certificate.

10-Q

11-8-22

4.2

5.1

Opinion of Latham & Watkins LLP.

X

23.1

Consent of Independent Registered Public Accounting Firm.

X

23.2

Consent of Latham & Watkins LLP (included in Exhibit 5.1).

X

24.1

Power of Attorney. Reference is made to the signature page to the Registration Statement.

X

99.1(a)#

2018 Incentive Award Plan.

S-8

5-7-18

99.2(a)

99.1(b)#

Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Incentive Award Plan.

S-1

4-5-18

10.4(b)

99.1(c)#

Form of Restricted Stock Award Grant Notice under the 2018 Incentive Award Plan.

S-1

4-5-18

10.4(c)

99.1(d)#

Form of Restricted Stock Unit Award Grant Notice under the 2018 Incentive Award Plan.

S-1

4-5-18

10.4(d)

99.2#

2018 Employee Stock Purchase Plan.

S-8

5-7-18

99.3

99.3(a)#

2020 Employment Inducement Incentive Award Plan

S-8

3-20-20

99.3(a)

99.3(b)#

Amendment to 2020 Employment Inducement Incentive Award Plan

S-8

11-24-20

99.3(b)

99.3(c)#

Second Amendment to 2020 Employment Inducement Incentive Award Plan

S-8

3-15-23

99.3(c)

99.3(d)#

Form of Stock Option Agreement under the 2020 Employment Inducement Incentive Award Plan, as amended

S-8

3-20-20

99.3(d)

99.3(e)#

Form of Restricted Stock Unit Award Agreement under the 2020 Employment Inducement Incentive Award Plan, as amended

S-8

3-20-20

99.3(e)

99.3(f)#

Form of Performance Stock Unit Award Agreement under the 2020 Employment Inducement Incentive Award Plan, as amended

S-8

3-20-20

99.3(f)

99.3(g)#

Form of Stock Award Agreement under the 2020 Employment Inducement Incentive Award Plan, as amended

S-8

3-20-20

99.3(g)

107

Filing Fee Table

X

 

---

# Indicates management contract or compensatory plan.

---

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California.

 

	Unity Biotechnology, Inc.
Date: March 7, 2025	By:		/s/ Anirvan Ghosh
			Anirvan Ghosh, Ph.D. Chief Executive Officer

 

 

---

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Anirvan Ghosh, Ph.D., Alexander Nguyen, and Lynne Sullivan, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on behalf of the Registrant, in the capacities and on the dates indicated.

Signature		Title		Date
/s/ Anirvan Ghosh Anirvan Ghosh, Ph.D.		Chief Executive Officer and Director (Principal Executive Officer)		March 7, 2025
/s/ Lynne Sullivan Lynne Sullivan		Chief Financial Officer (Principal Financial and Accounting Officer)		March 7, 2025
/s/ Keith R. Leonard Jr. Keith R. Leonard Jr.		Chairman		March 7, 2025
/s/ Paul L. Berns Paul L. Berns		Director		March 7, 2025
/s/ Nathaniel E. David Nathaniel E. David, Ph. D.		Director		March 7, 2025
/s/ Gilmore O’Neill Gilmore O'Neill, M.B.		Director		March 7, 2025
/s/ Margo Roberts Margo Roberts, Ph. D.		Director		March 7, 2025
/s/ Michael P. Samar		Director		March 7, 2025
Michael P. Samar
/s/ Camille D. Samuels		Director		March 7, 2025
Camille D. Samuels

 

---

Unity Biotechnology, Inc.

285 East Grand Avenue
South San Francisco, CA 94080

Re: Registration Statement on Form S-8; 1,011,912 shares of Common Stock of Unity Biotechnology, Inc., par value $0.0001 per share

 

To the addressee set forth above:

We have acted as special counsel to Unity Biotechnology, Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company of an aggregate of 1,011,912 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), consisting of 843,260 shares of Common Stock issuable under the 2018 Incentive Award Plan (the “2018 Plan”) and 168,652 shares of Common Stock issuable under the 2018 Employee Stock Purchase Plan (together with the 2018 Plan, the “Plans”).

The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on March 7, 2025 (the “Registration Statement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectuses, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of

---

the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor in excess of par value and in the circumstances contemplated by the Plans, assuming in each case that the individual issuances, grants or awards under the Plans are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the Plans (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and non-assessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Sincerely,

 

/s/ Latham & Watkins LLP

---

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2018 Incentive Award Plan and the 2018 Employee Stock Purchase Plan of Unity Biotechnology, Inc. of our report dated March 7, 2025, with respect to the financial statements of Unity Biotechnology, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

 

/s/ Ernst & Young LLP

 

San Mateo, California

March 7, 2025

 

---

Exhibit 107

Calculation of Filing Fee Tables

 

Form S-8

(Form Type)

 

Unity Biotechnology, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

	Security Type	Security Class Title	Fee Calculation Rule	Amount Registered (1)	Proposed Maximum Offering Price Per Share	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee(4)
Fees to Be Paid	Equity	Common Stock, $0.0001 par value per share	457(c) and 457(h)	843,260 (2)	$1.59 (3)	$1,340,784	$153.100 per $1,000,000	$206
Fees to Be Paid	Equity	Common Stock, $0.0001 par value per share	457(c) and 457(h)	168,652 (4)	$1.36 (5)	$229,367	$153.10 per $1,000,000	$36
Fees Previously Paid
	Total Offering Amounts					$1,570,151		$242
	Total Fees Previously Paid							–
	Total Fee Offsets							–
	Net Fee Due							$242

 

---

---